Agalimmune
focuses on developing an anti-cancer immunotherapy technology for the treatment of patients with solid tumors... Read moreAgalimmune
focuses on developing an anti-cancer immunotherapy technology for the treatment of patients with solid tumors... Read more
News
Mar 24, 2017
BioPortfolio
Agalimmune: BioLineRx Acquires Cancer Immunotherapeutics Company Agalimmune
Mar 23, 2017
FierceBiotechIT
Agalimmune: BioLineRx buys Agalimmune to expand cancer pipeline
May 25, 2016
BioSpace
Agalimmune: Agalimmune Limited To Present Novel Immunotherapy Targeting Patient-Specific Tumour Neoantigens At ASCO
Jun 17, 2015
CONTRACT PHARMA
Agalimmune: Agalimmune Licenses KODE Biotech's FSL Technology for Development of Cancer Immunotherapeutics
Jun 15, 2015
BIOSPACE
Agalimmune: Agalimmune Limited Licenses FSL Technology For Development Of Cancer Immunotherapeutics
Jun 15, 2015
BUSINESS WIRE
Press Release: Agalimmune : Agalimmune Licenses KODE Biotech's FSL Technology for Development of Cancer Immunotherapeutics
Jun 04, 2014
FORT MILL TIMES
Agalimmune: Agalimmune Receives £1.2 Million ($2 million) Milestone Payment
Agalimmune Competitors
1
2
3
4
5
6
7
8
9
10